Phase 2 study of RG1678 for the treatment of schizophrenia

Genentech announced eight-week results from a Phase 2 study of RG1678 for the treatment of schizophrenia. The data showed a clinically meaningful reduction in the negative symptoms of schizophrenia, accompanied by beneficial changes in patients' personal and social functioning. This study was a multicenter, randomized, double-blind, parallel group, 323-patient study investigating RG1678 compared to placebo in patients with predominantly negative symptoms of schizophrenia. In the study, the efficacy and safety profile of three dose regimens of RG1678 (10mg, 30mg and 60mg) were assessed. The primary efficacy endpoint was the change from baseline at week eight in the negative symptom factor score as assessed by the Positive and Negative Syndrome Scale (PANSS). Secondary endpoints were measured using the Clinical Global Impression (CGI)-Improvement in negative symptoms and Personal and Social Performance (PSP) scale. The study yielded the following results.